What is FDA’s AI plan for clinical trials?

FDA moves to speed up clinical trials using real-time AI review

The U.S. Food and Drug Administration announced efforts aimed at making clinical trials more efficient, including a plan to review information from ongoing trials in near real time. The initiative is part of a broader push to reduce the slow “dead time” between trial completion, data handling, and decision-making.

As described, the FDA’s approach begins with reviewing trial data in real time from trials that are already being conducted—using an AI-enabled workflow to help identify relevant findings sooner rather than waiting until all data are fully finalized. The goal is to shorten timelines in drug development, especially for trials where timely decision points could affect downstream regulatory actions.

This matters for patients and developers because clinical research is often bottlenecked by administrative and analytical delays after data collection ends. If regulators can assess key data streams earlier, sponsors may get faster clarification, and development programs could avoid waiting as long for confirmatory analysis.

How this could change the trial pipeline

• Faster regulator feedback during ongoing trials
• Potentially fewer late-stage surprises during review
• More efficient use of data already being generated

The announcement also aligns with other regulatory discussions about “smarter,” continuously monitored evidence and the need for trial designs that can accommodate updates. However, specific performance targets, which therapeutic areas are included first, and what exact AI methods will be used were not detailed in the reporting.

In short: the FDA is taking an early step toward integrating AI into clinical trial review to make drug development move at closer to the pace of data generation.